Life Sciences IPOs Take a Breather December 02, 2013 | Press Release
Booming IPO Market Improving M&A Terms for Private Biotechs November 01, 2013 | Press Release
ADMA Biologics, Inc. Announces Pricing October 18, 2013 | Press ReleaseSee all News
Jason Moran joined Burrill Securities in 2013 as a Consultant working in the Merchant Banking Group in the San Francisco office. He has more than 15 years of experience in the life sciences sector. Prior to joining Burrill Securities, Moran served as a Managing Director in the Healthcare Group at Stifel Nicolaus Weisel and a Managing Director in the healthcare group at Piper Jaffray. He started his career at Banc of America Securities and has also held operating positions at MDS Analytical Technologies and Affymetrix.
Moran has broad-based deal experience across the biopharmaceutical, medical technology and tools/diagnostics sub-sectors. His deal experience encompasses equity offerings, debt offerings and M&A transactions and includes over 110 transactions representing nearly $15 billion in value. He has extensive experience covering Japanese pharmaceutical companies and represented Dainippon Sumitomo Pharma (now Sunovion) in its $2.5 billion acquisition of Sepracor.
He received a B.A. in Biology from Yale University.